Redhill Biopharma Ltd. (NASDAQ:RDHL) Stock Short Interest Declines 39.2%

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a significant drop in short interest in October. As of October 15th, there was short interest totaling 128,328 shares, a drop of 39.2% from the September 30th total of 211,200 shares. Based on an average trading volume of 1,568,822 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.5% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Redhill Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 6th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Redhill Biopharma Stock Down 6.9%

Redhill Biopharma stock opened at $0.39 on Friday. Redhill Biopharma has a one year low of $0.38 and a one year high of $1.60. The business’s fifty day moving average is $0.56 and its 200 day moving average is $0.81.

About Redhill Biopharma

RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and infectious diseases. The company was founded in Israel and later operated as a publicly traded company in the United States under the ticker symbol RDHL.

RedHill’s principal commercial product was Talicia, an oral combination of omeprazole, amoxicillin and rifabutin approved by the U.S. Food and Drug Administration for the treatment of Helicobacter pylori infection in adults.